Evercyte bringing latest cell-based advances at BIO-Europe

Vienna, Austria: – Innovative biotech manufacturer Evercyte will use the prestigious European pharma partnering event, BIO-Europe, to showcase its recently launched recombinant human vascular endothelial growth factor, VEGF165, cost-effectively produced in Pichia pastoris.

Evercyte will exhibit as part of the LISAvienna Austrian Collective at Booth 84, in the upper area of the exhibition. It will also co-host the “Wiener Heurigen Reception” hospitality event on the evening of Day Two of the meeting, starting at 17:45 hrs at the LISAvienna stand.

VEGF 165

The Evercyte team at BIO-Europe, led by CEO Otto Kanzler and Chief Scientific Officer Johannes Grillari, will be sharing details on VEGF165, produced in in Pichia pastoris, including its greater than 97% purity, and biological activity, tested using Evercyte’s human endothelial cell line HUVEC/TERT2.

VEGF plays a key pleiotropic role in vasculogenesis, inducing endothelial cell proliferation and promoting cell migration along with formation of new blood vessels.

Human Podocyte

“We always look forward to the BIO-Europe event, which we have been attending for many years now.” says Prof. Johannes Grillari, CSO and co-founder of Evercyte. “At this year’s BIO we are going to present our most recent product – VEGF 165 – along with information on new cell lines now being added to our product catalogue within the next few months, particularly a human Podocyte cell line.

Evercyte has been a regular presence at BIO-Europe summits and partnering meetings, using the event at a potent platform for meeting current and potential customers and collaboration partners to discuss in-licensing and out-licensing opportunities for its cell-based drug discovery technologies.

At last year’s BIO event in Munich, Evercyte announced it had made significant advances in ADME/Tox analysis of absorption, distribution, metabolism, and excretion disposition of substances, along with human telomerase reverse transcriptase (hTERT) and technologies for patient specific induced pluripotent stem cells (iPSCs) from urine.

About Evercyte

Evercyte GmbH, based in Vienna, manufactures a range of innovative cell-based products; including primary/normal cells; telomerase (hTERT) immortalized or life span extended cells and differentiated cells from immortalized or normal stem cells.

Recently, Evercyte has become a key player in the development of induced pluripotent stem (iPS) cells from human urine as a non-invasive source for generating cell material. The company also offers a range of cell-based assays, used in development of drug screening strategies and other applications. It also develops assays to individual specification to help customers reduce their time and spend on drug discovery and development.

Evercyte’s Pharmacocellomics™ is also improving the predictability of substance efficiencies and side effects in the general population by systematically establishing and commercializing relevant cell type specific model systems from donors of different genetic backgrounds.

About BIO-Europe 2016

The BIO-Europe® Conference is the flagship conference for EBD Group, providing life science companies with high caliber knowledge sharing and partnering opportunities.

BIO-Europe 2016 is a three-day event opening November 7 at Cologne’s Köln Messe – Congress Center North.

BIO-Europe has formed the launchpad for many highly successful business partnerships, drawing delegates from all parts of the biotechnology value chain to identify, engage and enter into strategic relationships.

This year´s BIO-Europe partnering event will again draw over 3,000 industry attendees from nearly 60 countries, representing more than 1,800 companies for three days of high level networking.

Partnering at BIO-Europe 2016 is powered by EBD Group’s partneringONE®, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with multiple company targets.

More information: https://ebdgroup.knect365.com/bioeurope/